Mitozolomide

Mitozolomide
	;
IUPAC name	3-(2-chloroethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide ; ; ; ; ; ; ; ; ;
CAS Number	85622-95-3
PubChem	71766 ;
ChemSpider	64805 ; ;
Molecular weight	242.622 g/mol

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.^[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.^[2]

References[edit]

↑ "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide".Cancer Gene Ther.February 2000;7(2)
233–9.doi:10.1038/sj.cgt.7700120.PMID:10770631.Full text.
↑ "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)".Br J Cancer.February 1992;65(2)
287–91.doi:10.1038/bjc.1992.57.PMID:1739631.PMC:1977719.

This medical article is a stub. You can help WikiMD by expanding the page.

Mitozolomide

Navigation-> Medicine - Wellness - Encyclopedia - Health topics - Diseases - Drugs - Gray's Anatomy - W8MD diet - Ketogenic diet - Recipes

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Translate this page: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian

[1] "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide".Cancer Gene Ther.February 2000;7(2)
233–9.doi:10.1038/sj.cgt.7700120.PMID:10770631.Full text.

[2] "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)".Br J Cancer.February 1992;65(2)
287–91.doi:10.1038/bjc.1992.57.PMID:1739631.PMC:1977719.

[1]

[2]